Advertisement
U.S. markets closed

DBV Technologies S.A. (DBVT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.8390+0.0130 (+1.57%)
At close: 04:00PM EST
0.8390 0.00 (0.00%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Top

Double Top

Previous Close0.8260
Open0.8200
Bid0.8250 x 4000
Ask0.8400 x 1800
Day's Range0.8038 - 0.8400
52 Week Range0.6500 - 2.3700
Volume32,324
Avg. Volume309,054
Market Cap161.401M
Beta (5Y Monthly)0.83
PE Ratio (TTM)N/A
EPS (TTM)-0.5500
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.01
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DBVT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • DBV Technologies S.A.
    Daily – Vickers Top Buyers & Sellers for 02/12/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    13 days agoArgus Research
View more
  • GlobeNewswire

    DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

    Montrouge, France, February 20 2024 DBV Technologies to Participate in Upcoming AAAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –NASDAQ: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced two presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting, February 23-26 in Washington, D.C. A poster presentation by David Fleischer, M.D. of Children’s Hospital Colorado will describe t

  • GlobeNewswire

    Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

    AMF Regulated InformationMontrouge, France, January 16, 2024 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with NATIXIS ODDO BHF. Under the liquidity contract between DBV Technologies and NATIXIS ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2023:

  • GlobeNewswire

    Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023

    Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights11/30/2023 96,431,770 Total gross of voting rights: 96,431,770 Total net* of voting rights: 96,186,256 * Net total = total number of voting rights attached to shares – shares without v